A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine

Inclusion criteria:

All patients:

1. Patient is ongoing on brigimadlin treatment or qualifies for crossover tobrigimadlin treatment in any trial sponsored by Boehringer Ingelheim (hereafterreferred to as the 'parent trial').

2. Provision of signed and dated, written informed consent form (ICF) in accordancewith International Council for Harmonisation of Technical Requirements forPharmaceuticals for Human Use - Good Clinical Practice (ICH-GCP) and locallegislation prior to any trial-specific procedures, sampling, or analyses.

3. Women of childbearing potential (WOCBP) and men able to father a child must be readyand able to use 2 medically acceptable methods of birth control per ICH M3 (R2) thatresult in a low failure rate of <1% per year when used consistently and correctlybeginning at Screening, during trial participation, and until 6 months and 12 daysafter the last dose for women and 102 days after the last dose for men. A list ofcontraception methods meeting these criteria and instructions on the duration of useis provided in the participant information.

4. Participants must be willing and able to comply with the scheduled visits, treatmentplan, lifestyle, laboratory tests, contraceptive guidelines, and other studyprocedures.

5. Adequate organ function.

6. All toxicities related to previous anti-cancer therapies have resolved CommonTerminology Criteria for Adverse Events (CTCAE) Grade ≤1 prior to trial treatmentadministration (except for alopecia and amenorrhea/menstrual disorders which can beany grade and peripheral neuropathy which must be CTCAE Grade ≤2). Cohort 1 only:

7. Patient is eligible to receive continued treatment according to the clinical trialprotocol of the parent trial they are currently participating in. Patients currentlyexperiencing a dose delay in the parent trial due to adverse events are eligible ifrecovery from the adverse event takes place within the allowed time window in theparent trial. Cohort 2 only:

8. Patient is eligible to receive crossover treatment according to the clinical trialprotocol of the parent trial they are currently participating in. Patients musttransition directly from the parent trial to this trial, with no further anti-cancertherapies except those that are allowed by the clinical trial protocol of the parenttrial.

Further inclusion criteria apply.

Exclusion criteria:

1. Any medical condition which in the opinion of the investigator should exclude thepatient from receiving treatment with brigimadlin.

2. Participants who must receive or intend to receive restricted medications or anydrug considered likely to interfere with the safe conduct of the trial.

3. Women who are pregnant, nursing, or who plan to become pregnant while in the trial.Female patients who do not agree to the interruption of breastfeeding from the startof study treatment until 6 months and 12 days after the last dose of studytreatment. Cohort 1 only:

4. Patient has disease progression or unacceptable toxicity on brigimadlin at the timeof transition into this trial.

5. Patient has an adverse event (AE) which has caused a dose delay and has notrecovered within the allowed time window in the parent trial.

6. Patient who has already required 2 dose reductions and would require a third dosereduction at trial entry, unless the investigator deems treatment continuationbeneficial, and the third dose reduction is agreed between the investigator and thesponsor.

Further exclusion criteria apply.